Back to results
US 2026/0309709 A1Published application
Ace2 inhibition assay for evaluation of vaccine immunogenicity
AssigneeNovavax, Inc.
InventorsJoyce S. PLESTED, Raj KALKERI
Life of this patent
Estimating the term…
Abstract
An improved assay to measure immunogenicity of vaccines while overcoming some of the limitations of current biomarkers of immunogenicity is necessary. Disclosed herein is an assay for measuring inhibition of binding between SARS-CoV-2 Spike (S) glycoproteins and hACE2. Also provided herein are methods of using the assay to evaluate the efficacy of COVID-19 vaccines.
Claims17
A method for determining if a biological sample contains antibodies that inhibit binding of a SARS-CoV-2 S glycoprotein to human angiotensin-converting enzyme 2 (hACE2), comprising:
- (a) measuring binding of a SARS-CoV-2 S glycoprotein to hACE2 after exposure to a biological sample by:
- (i) providing a surface coated with the SARS-CoV-2 S glycoprotein;
- (ii) exposing the surface to the biological sample;
- (iii) exposing the surface to hACE2;
- and
- (iv) detecting hACE2 that is bound to the surface;
- (b) measuring binding of a SARS-CoV-2 S glycoprotein to hACE2 in the absence of the biological sample of (a) by:
- (i) providing a surface coated with the SARS-CoV-2 S glycoprotein;
- (ii) exposing the surface to hACE2;
- and
- (iii) detecting hACE2 that is bound to the surface;
- and
- (c) comparing binding of the SARS-CoV-2 S glycoprotein to hACE2 in (a) and (b);
- wherein a biological sample contains antibodies that inhibit binding of the SARS-CoV-2 S glycoprotein to hACE2 if the amount of bound hACE2 in (a) is less than the amount of bound hACE2 in (b).
11 more elements
Dependencies are inferred from the claim text.